Moderna, Inc.
MRNA
Below: live stock price for Moderna, Inc. (MRNA), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Moderna, Inc. (MRNA) trades at 61.82 USD on investpig.
- Prev close
- $63.15
- Volume (24h)
- $281.40M
- Market cap
- $24.53B
- Currency
- USD
Score
50/ 100 · Mixed
- Value—
- Quality—
- Momentum—
- Growth—
- Risk—
- Dividend—
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 63.7062 +3.05%
- +20 bars
- 66.4036 +7.41%
- +60 bars
- 67.4774 +9.15%
- +120 bars
- 67.5171 +9.22%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.1137 USD.
Interpretation
Price sits in the middle of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
- ResistanceFib +161.8% extension153.4266 USD+148.18% from current
- ResistanceFib +100% extension127.52 USD+106.28% from current
- ResistanceFib +61.8% extension111.5066 USD+80.37% from current
- ResistanceFib +27.2% extension97.0022 USD+56.91% from current
- ResistanceFib 23.6% retracement75.7069 USD+22.46% from current
- ResistanceFib 38.2% retracement69.5866 USD+12.56% from current
- ResistanceFib 50% midpoint64.64 USD+4.56% from current
- Current61.82 USD
- SupportFib 61.8% retracement59.6934 USD-3.44% from current
- SupportFib 78.6% retracement52.6509 USD-14.83% from current
- SupportFib −27.2% extension32.2778 USD-47.79% from current
- SupportFib −61.8% extension17.7734 USD-71.25% from current
- SupportFib −100% extension1.76 USD-97.15% from current
Recent news
- Microsoft CEO’s Anthropic criticism reveals bigger AI power struggleTheStreet40m ago
- Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLCPR Newswire4h ago
- Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and IndiaPR Newswire11h ago
- UnitedHealth CFO sends stark warning after earningsTheStreet19h ago
- MRNA Advances Cancer Pipeline With New Immunotherapy StudyZacks2d ago
- 14 S&P 500 Stocks Are Up Over 100% in 2026. Why Micron Is My Favorite for the Rest of the Year.Barchart1d ago
- Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?StockStory2d ago
- CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.